Nanotech risk survey
This article was originally published in The Tan Sheet
Executive Summary
The German Federal Institute for Risk Assessment (BfR) is conducting an expert survey on the risk of nanotechnology, the agency announces Aug. 22. The expert survey will focus on nanotechnology in foods, cosmetics and consumer goods. About 100 experts will participate in the multi-phase qualitative forecasting survey discussing current and future applications of nanotechnology and the opportunities and risks for consumers, the agency says. "The objective is to identify already used or potentially usable nanomaterials, assign them to concrete applications and then draw conclusions on consumer exposure," the institute states. Toward the end of the year, BfR will stage a "Consumer Conference on Perception of Nanotechnology." A final report on the conference will be made available to industry, "main stakeholders in the political circles," public agencies, scientists and non-governmental organizations, according to the release. "Both projects will help to identify scientifically determined and emotionally perceived risks early on and to carry them over to the communication process," BfR President Andreas Hensel states...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.